DESTINY-Gastric02: Trastuzumab Deruxtecan in Western Patients With HER2+ Advanced Gastric or GEJ Cancer With Progression Following First-line Trastuzumab-Containing Therapy

September 16-21, 2021; Virtual
In this single-arm phase II trial, second-line therapy with trastuzumab deruxtecan showed a response rate of 38% and durable responses following a trastuzumab-containing regimen in Western patients with HER2+ advanced gastric or GEJ cancer with no unexpected adverse events.
Format: Microsoft PowerPoint (.ppt)
File Size: 248 KB
Released: September 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Exelixis, Inc.
Ipsen Biopharmaceuticals, Inc.

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021

Updated results from CheckMate 649 confirm OS benefit of addition of nivolumab to first-line chemotherapy in gastroesophageal cancers, from ESMO 2021 as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue